Researchers at Wake Forest University School of Medicine conducted a Phase III randomized, placebo-controlled trial to test donepezil, a cognitive-enhancing medicine used in the treatment of Alzheimer’s disease. The research team found that donepezil did not improve memory or other cognitive functions in survivors with cancer-related cognitive impairment.
Up to 18% of patients undergoing ACL reconstruction experience graft failure and require revision surgery, which is known to increase the risk of developing post-traumatic osteoarthritis (PTOA).
The University of Illinois Chicago study will be the first to assess whether the natural product has anti-cancer effects that could benefit patients as they await surgical treatment.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced that it has advanced new preclinical studies using Ketamir-2, its differentiated oral ketamine analog, towards clinical development for the treatment of severe post-traumatic stress disorder (PTSD) and other leading mental health disorders and neuropathic pain indications.
Dr. Hyuk-June Moon from the Bionics Research Center at the Korea Institute of Science and Technology (KIST), in collaboration with Prof. Olaf Blanke’s team at the Swiss Federal Institute of Technology Lausanne (EPFL), has successfully induced self-location illusions with multi-sensory virtual reality (VR) in the MRI scanner and observed corresponding changes in the human brain's grid cell activity.
A recent publication in Scientific Reports unveils a potentially groundbreaking non-opioid pain treatment developed by a team led by Dr. Hernan Bazan.
Randomized controlled trials have long been the gold standard for evaluating new therapies. But for pediatric brain tumors, it can be difficult—if not impossible—to enroll the large numbers of patients needed for these studies.
Sylvester Comprehensive Cancer Center today announced establishment of the Sylvester Brain Tumor Institute. It will focus on personalized medicine approaches for treating all patients with brain tumors.
ChatGPT, the artificial intelligence (AI) chatbot designed to assist with language-based tasks, can effectively extract data for research purposes from physicians' clinical notes, UT Southwestern Medical Center researchers report in a new study. Their findings, published in NPJ Digital Medicine, could significantly accelerate clinical research and lead to new innovations in computerized clinical decision-making aids.
The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to the ”Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage (E-MOTIVE).”
The first U.S. heart patient involved in a study for a new gene-editing therapy has successfully been treated at MedStar Washington Hospital Center.
The Angeles Clinic and Research Institute, an affiliate of Cedars-Sinai Cancer, is teaming up with the AIM at Melanoma Foundation for the 14th year to host a free melanoma symposium for patients, caregivers and clinicians.
Patients in South Florida with metastatic melanoma will soon have access to tumor-infiltrating lymphocyte therapy, or TIL. The therapy will be available at Sylvester Comprehensive Cancer Center and will be South Florida’s only center offering this treatment.
Researchers at Wake Forest University School of Medicine have been approved for a $1 million award by the Patient-Centered Outcomes Research Institute (PCORI) for a methodology study.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for April 2024.
Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following initial frontline standard of care immunotherapy that includes an immune checkpoint inhibitor alone or combined with chemotherapy.
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer Research (AACR) Annual Meeting 2024.
A pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy before surgery is safe and may improve long-term outcomes.
SEATTLE — April 3, 2024 — Below are summaries of recent Fred Hutchinson Cancer Center research findings, patient stories and other news. If you’re covering the American Association for Cancer Research (AACR) Annual Meeting, please see our list of and contact to set up interviews.
The Wilmer Eye Institute, Johns Hopkins Medicine has received two awards totaling more than $20 million from the National Eye Institute at the National Institutes of Health, both of which will be used for a six-year clinical trial investigating a potential treatment for the most common inherited retinal disease, retinitis pigmentosa.
Curtis L. Cetrulo Jr., MD, vice chair of Research in the Department of Surgery and director of the Division of Plastic Surgery, has been selected as the General William and Willa Dean Lyon Family Chair in Reconstructive and Plastic Surgery.
Researchers from Fred Hutchinson Cancer Center, the American Cancer Society Cancer Action Network and peer institutions released new findings in the Journal of Clinical Oncology showing that when all types of cancer research studies are considered, at least one in five people with cancer in the U.S., or 21.9%, participate in some form of clinical research.
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
A 'Comprehensive Cancer Center' is the top U.S. designation for cancer research and treatment facilities recognized by high-quality research that leads to major shifts in cancer care.
A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.
A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a study published today in Science Advances.
A gene therapy developed by researchers at UT Southwestern Medical Center for a rare disease called giant axonal neuropathy (GAN) was well tolerated in pediatric patients and showed clear benefits, a new study reports. Findings from the phase one clinical trial, published in the New England Journal of Medicine, could offer hope for patients with this rare condition and a host of other neurological diseases.
UCI Health, the clinical enterprise of the University of California, Irvine, has completed the acquisition of four hospitals and associated outpatient locations from Tenet Healthcare Corporation.
Mariam F. Eskander, MD, MPH, surgical oncologist in the Gastrointestinal Oncology Program at Rutgers Institute of New Jersey, offers insight and tips for minority individuals navigating a cancer diagnosis and how we can all work together to mitigate cancer disparities.
Head and neck cancer is the term used to describe a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth.
For years, it was harder for Black patients to secure a coveted spot on the national kidney transplant waitlist because a clinical algorithm was making Black patients appear healthier than they were.
The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study at the National Eye Institute (NEI), part of the National Institutes of Health.
ScienceMedia, a global SaaS provider redefining the landscape of clinical mastery in the biotech and pharma industries, announces the formation of its inaugural advisory board.
A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.
The ATS 2024 International Conference Program is now live! Get ready for a series of dynamic scientific programming with presentations covering AI in thoracic medicine, the basic sciences, research breakthroughs and clinical treatment, as well as spotlighting the next generation of innovators in pulmonary, critical care and sleep medicine.
In the first clinical trial of a targeted pharmacologic therapeutic for mild traumatic brain injury in pediatric patients, scientists have found preliminary evidence that adolescents and young adults with concussion who take a specific formulation of branched chain amino acid (BCAA) supplements after injury experience faster symptom reduction and return to physical activity.
Scientists at St. Jude Children’s Research Hospital have uncovered a metabolic role for cell-survival protein MCL-1, potentially explaining previous clinical trial setbacks.
20240208171546.png&width=400&height=400)
A team at Memorial Sloan Kettering Cancer Center (MSK) led by thoracic surgeon Prasad Adusumilli, MD, has been awarded a distinguished UG3/UH3 grant from the National Cancer Institute (NCI) to advance research and testing of chimeric antigen receptor (CAR) T cell therapy for solid tumors.
New Cleveland Clinic-led research provides evidence that video laryngoscopy significantly decreased the number of attempts needed to achieve intubation in adult surgical patients who required single-lumen endotracheal intubation for general anesthesia, compared with direct laryngoscopy. The research was published today in JAMA.
St. Baldrick’s Foundation Awards $50,000 Grant to Expand Pediatric Cancer Clinical Trials at K. Hovnanian Children’s Hospital
Resmetirom (Rezdiffra) is the first drug approved for treating MASH, an advanced form of fatty liver disease. UChicago Medicine experts contributed to a recent clinical trial and will begin incorporating the drug into liver disease treatment regimens for eligible patients.
Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented positive interim data from a diabetic foot ulcer (DFU) clinical trial showing that Omeza® OCM™ plus offloading of weight on the affected foot achieved a 91 percent area reduction (PAR) rate in DFUs within twelve weeks, and a 63 percent PAR within four weeks.
A clinical trial from Keck Medicine of USC aims to provide a surgical solution for patients with a form of advanced pancreatic cancer previously considered inoperable.
“This is the largest annual research budget in our 46-year history,” said Thomas M. Brunner, GRF President and CEO.
A high impact study led by Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer. This work is published in JAMA Oncology.
The Phase 3 CELLEBRATE trial to test a regenerative stem cell-based therapy in treating patients with stress urinary incontinence is continuing to recruit additional subjects after changing its study protocol to include only patients who have already tried surgery.
In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.
The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the first on the West Coast to use a new device aimed at lowering blood pressure in patients with difficult-to-treat hypertension.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
